Overview
Description
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Japan
Financials
Key metrics
Market capitalisation, EUR | 12,667.21 m |
EPS, EUR | 1.22 |
P/B ratio | 1.45 |
P/E ratio | 11.58 |
Dividend yield | 2.64% |
Income statement (2024)
Revenue, EUR | 2,681.22 m |
Net income, EUR | 1,042.68 m |
Profit margin | 38.89% |
What ETF is Shionogi & Co., Ltd. in?
There are 254 ETFs which contain Shionogi & Co., Ltd.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Shionogi & Co., Ltd. is the HSBC MSCI Japan Climate Paris Aligned UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.